Cell and gene therapies are niche ones and hence giant pharma firms are adding new products to existing product line, thereby enhancing manufacturing capacities.
Cell and gene therapies are niche ones and hence giant pharma firms are adding new products to existing product line, thereby enhancing manufacturing capacities. Apart from this, mammoth pharma companies such as Thermo Fisher, Novartis, Catalent, and Roche are investing millions of dollars to improve manufacturing capacity of products used in cell & gene treatments, thereby enlarging scope of cell and gene therapy manufacturing business. Precisely, in cell therapy, cells are modified out of patient body and then again injected into the body of patient, thereby making them function as live medicine. In gene therapy, gene is either deactivated, substituted, or introduced into human cells which are inside human body or taken outside human body. Gene therapy is utilized for treating various kinds of chronic disorders in living beings. Apparently, gene as well as cell treatments are designed for halting disease proliferation as well as reversing growth of disease.
Furthermore, giant firms are investing massively in cell & gene treatment research activities and expanding their base through acquisitions. Citing an instance, in 2019, Novartis purchased CELLforCure – a largest French-based contract development & manufacturing organizations manufacturing cell & gene treatments – from LFB. Furthermore, acquisition encompassed cell & gene manufacturing unit situated in outskirts of Paris. The strategic move was aimed at developing effective CAR-T cell treatments as well as expanding research activities & base of Novartis in cell & gene therapy domain in France. Reportedly, firms such as Novartis has taken many steps for reinforcing & expanding its cell & gene manufacturing activities through entering into licensing, collaboration, and purchase agreement with Cellular Biomedicine Group for producing as well as supplying Kymriah – first CAR-T cell treatment approved by U.S. FDA - to China. Apart from this, Novartis formed alliance with Fraunhofer institute in Germany for facilitating cell & gene manufacturing for clinical tests & post approval cell & gene manufacturing. It had also entered into contract cell & gene manufacturing agreement with Japan. All these aforementioned aspects will assist cell and gene therapy manufacturing market explore new paths of growth in upcoming years.
The global Cell and Gene Therapy Manufacturing market accrued earnings worth approximately 12.59 (USD Billion) in 2020 and is predicted to gain revenue of about 23.21(USD Billion) by 2028, is set to record a CAGR of nearly 20.2% over the period from 2021 to 2028. The report offers assessment and analysis of the Cell and Gene Therapy Manufacturing market on a global and regional level.
Evolution of new therapies has brought a paradigm shift in biopharma sector and will revolutionize life-threatening & rare disease treatment, thereby steering growth of cell and gene therapy manufacturing market. In addition to this, rapid spread of COVID-19 virus across the globe has favorably influenced expansion of cell and gene therapy manufacturing market size. Regulations supporting use of cell & gene treatments for various diseases will augment scope of cell and gene therapy manufacturing market growth in forthcoming years. Decentralized manufacturing of cell and gene therapies is likely to bring a drastic transformation in cell & gene therapy manufacturing approach, thereby driving market trends. Mergers & acquisitions have also shaped growth of cell and gene therapy manufacturing industry in recent years. Citing an instance, in May 2019, Catalent Inc. - a leading provider of drugs, consumer health products, and biologics- acquired Paragon BioServices Incorporation- a major viral vector developer & provider of manufacturing solutions for gene treatments- for nearly USD 1.2 billion. Reportedly, in May 2019, Thermo Fisher Scientific Inc. acquired Brammer Bio- a major viral vector producer for cell and gene treatments- for nearly USD 1.7 billion in cash. In April 2019, Hitachi Chemical- a Japanese firm manufacturing chemicals- acquired apceth Biopharma GmbH- a Germany based CDMO for gene & cell treatments- for nearly USD 86.5 million with a view for expanding its business in new cell & gene therapy contract development & manufacturing solutions domain. Additionally, the strategic move is aimed at development of regenerative drug business in the U.S., Japan, and Europe, thereby not only expanding its regional base but to accrue huge profits by entering in niche business of cell & gene manufacturing & launching differentiated & innovative products. Earlier in 2017, Hitachi had purchased PCT, LLC – a U.S. headquartered contract producer of regenerative drugs- and then had commenced its manufacturing & contract development operations for producing regenerative drugs in April 2018 at its new unit in Yokohama, Japan.
Apart from this, new entrants are also likely to shape growth of cell and gene therapy manufacturing market in foreseeable future. For instance, small firm such as bluebird bio- a Massachusettes-based gene & cell therapy firm- had set up its cell and gene therapy manufacturing establishment in Durham in March 2019 with an objective for producing lentiviral vector to investigate gene & cell treatments. Moreover, in 2018, Abeona Therapeutics – a Texas-based biopharma firm- established a GMP manufacturing unit in Cleveland in the U.S. with an aim to carry out research on gene & cell treatments. During same year, Mustang Bio- a New York based biopharma organization, inaugurated a CAR T cell treatment manufacturing base at Worcester in Massachusetts in the U.S.
Furthermore, gene and cell based treatments possess huge potential for offering new modes of treatment for several severe ailments and this will pave a way for humungous growth of cell and gene therapy manufacturing market in coming decade. With new insights in disease biology & evolution of new cellular mechanisms has resulted in rapid development & production of regenerative & immunotherapeutic medicines, thereby aiding growth of cell and gene therapy manufacturing industry over the assessment period.
Regional Landscape
North America To Contribute Majorly Towards Market Size By 2028
The growth of cell and gene therapy manufacturing market in North America over assessment period is owing to surge in proportion of clinical studies in countries such as the U.S. In addition to this, increase in funding of research activities pertaining to cell & gene treatments will further boost scope of market in the sub-continent over the following years. Apart from this, large-scale presence of firms into cell & gene therapy business in the sub-continent will drive the business landscape in region over forecast timeline. New product development, mergers & acquisitions, partnerships, agreements, strategic alliances & collaborations between firm, and licensing of drugs & medicine patenting or trade copyrights have favorably influenced regional market growth.
Get Sample of this Research Report for more Insights – https://www.zionmarketresearch.com/sample/cell-and-gene-therapy-manufacturing-market
Competitive Landscape
Key participants profiled in report and influencing market proceeds include Lonza AG, Thermo Fisher Scientific, Merck KGaA, Catalent Inc., Roche Diagnostics Limited, Takara Bio Incorporation, Boehringer Ingelheim, Wuxi Advanced Therapeutics, Novartis AG, Hitachi Chemical Company Limited, Bluebird Bio Inc., and Cellular Therapeutics.
About Us
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Contact Us –
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com